All AbMole products are for research use only, cannot be used for human consumption.
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research.
| CAS Number | 1655501-53-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[1] No authors listed. Aust Prescr. Fremanezumab for migraine
[2] No authors listed. Fremanezumab
| Related CGRP Receptor Products |
|---|
| Rimegepant
Rimegepant, also known as BMS-927711, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist with a Ki value of 0.027 nM. |
| BAR 501 impurity |
| BAR501
BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. |
| Olcegepant (BIBN-4096)
Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide (CGRP) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP. |
| Vazegepant hydrochloride
Vazegepant (BHV-3500) hydrochloride is a first-in-class, high affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). Vazegepant hydrochloride may be useful in the effective treatment of lung inflammation associated with COVID-19. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
